San Diego, CA (PRWEB) June 28, 2011
Ivera Medical Corporation has been awarded a new contract with Premier Purchasing Partners, LP, the group purchasing unit of the Premier healthcare alliance, for its Curos® Port Protector. This contract was awarded through Premier’s Sourcing Education and Enrichment for Diverse and Small Suppliers (SEEDS) program, a supplier diversity program that aims to increase the number of minority-, women-, veteran-owned and small business enterprises doing business with Premier alliance members.
Beginning June 15, 2011 and extending through January 2014, the agreement allows Premier members to access special contract pricing for the Curos Port Protector, a simple, innovative, disposable medical device that guards against infection by keeping luer-activated needleless valve access ports protected and clean.
With two dispenser options—the Curos Strip or individual Curos—nurses can conveniently comply with disinfection protocols by simply peeling the foil seal off the distinctive green cap and twisting Curos over the top of any luer-activated IV access port or needleless valve. Inside Curos a 70% IPA (isopropyl alcohol) saturated sponge-like foam automatically provides effective, consistent and reliable passive disinfection of the port.
Bob Rogers, Ivera Medical’s CEO stated, “Curos is a powerful, yet simple, tool designed to help hospital’s reduce bloodstream infection rates. Yes, at its core, Curos is basically alcohol in a cap – but each Curos port protector is engineered to deliver optimal results, from its efficiently minimal packaging, to its luer-lock design which complies with the 2011 INS Standards of Practice to its bright green color which helps hospitals monitor compliance at a glance thereby easily meeting The Joint Commission’s requirements. Nurses love Curos, it is simple to use, reduces time required for disinfection and eliminates user technique variability.”
A recent study conducted by a university hospital found Curos’ passive disinfection reduced central line associated bloodstream infections (CLABSI) and contaminated blood cultures. The study conducted in a 12-bed bone marrow transplant unit and 20-bed oncology unit, demonstrated to the researchers an 86.2 percent reduction in CLABSI and a 92 percent fall in contaminated blood cultures equating to an estimated annualized cost avoidance of $500,000. Researchers concluded that the efficacy of Curos, in part, is ascribed to the easily monitored disinfection compliance (greater than 85 percent on average.)
“Contracting with Premier is an important step in our efforts to help hospitals and patients greatly reduce the epidemic of bloodstream infections which currently take a devastating toll on healthcare finances and human lives,” said Rogers.
About Ivera Medical
Ivera Medical Corporation is focused on the design, development, manufacture, marketing and sale of products that help healthcare providers reduce facility-acquired patient infections. Curos, manufactured in Carlsbad, CA, is the first disinfecting cap to be marketed in the U.S. and has received FDA’s 510(k) market clearance. For more information about Curos and Ivera Medical, visit the website at http://www.iveramed.com.
About Premier, Inc.
Premier is a performance improvement alliance of more than 2,500 U.S. hospitals and 75,000 other healthcare sites using the power of collaboration to lead the transformation to high quality, cost-effective care. Owned by hospitals, health systems and other providers, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier has worked with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has an office in Washington. http://www.premierinc.com.